These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1745 related articles for article (PubMed ID: 29061175)

  • 41. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B; Zuo B; Huang L; You X; Liu T; Hao J; Yuan C; Yang C; Yee Lau W; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112492. PubMed ID: 38906005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.
    Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS
    Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.
    Chen S; Yuan B; Yu W; Wang X; He C; Chen C
    J Gastrointest Surg; 2022 Nov; 26(11):2292-2300. PubMed ID: 35920966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu J; Zhang J; Wang Y; Shu G; Lou C; Du Z
    Medicine (Baltimore); 2022 Dec; 101(51):e32390. PubMed ID: 36595819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
    Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
    Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
    JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
    Lyu N; Kong Y; Pan T; Mu L; Li S; Liu Y; Deng H; Li J; Shi M; Xu L; Guo R; Chen M; Wu P; Zhao M
    J Vasc Interv Radiol; 2019 Mar; 30(3):349-357.e2. PubMed ID: 30819477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
    Ishida K; Hirooka M; Hiraoka A; Kumagi T; Uehara T; Hiasa Y; Horiike N; Onji M
    Jpn J Clin Oncol; 2008 Sep; 38(9):596-603. PubMed ID: 18772170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
    Lim A; Le Sourd S; Senellart H; Luet D; Douane F; Perret C; Bouvier A; Métairie S; Cauchin E; Rougier P; Matysiak-Budnik T; Touchefeu Y
    Clin Colorectal Cancer; 2017 Dec; 16(4):308-315. PubMed ID: 28433600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
    Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
    J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.